THOUSAND OAKS, Calif.--(BUSINESS WIRE)--April 10, 2007--Amgen
(NASDAQ: AMGN) today announced the appointment of Robert Bradway as
executive vice president and chief financial officer. He will be
responsible for Amgen´s finance, strategy and investor relations
operations. Bradway replaces Richard Nanula, who is leaving the
company to pursue other opportunities.
Bradway, 44, joined Amgen in 2006 as vice president, Operations
Strategy. Prior to joining the company, he spent 18 years at Morgan
Stanley in New York and London, where he was a managing director in
investment banking. Bradway led Morgan Stanley´s healthcare practice
in Europe for several years and also ran the company´s European
"Bob brings nearly 20 years of corporate finance experience to his
new role and we are delighted to have him as part of our executive
team," said Kevin Sharer, Amgen´s chairman and chief executive
Nanula will remain at Amgen for the next 90 days to assist in the
transition. "Richard has played an important role in Amgen´s growth
during the past six years, and I deeply appreciate his service to the
company," said Sharer.
Amgen discovers, develops and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the
first companies to realize the new science´s promise by bringing safe
and effective medicines from lab, to manufacturing plant, to patient.
Amgen therapeutics have changed the practice of medicine, helping
millions of people around the world in the fight against cancer,
kidney disease, rheumatoid arthritis, and other serious illnesses.
Amgen remains committed to advancing science to dramatically improve
people´s lives. To learn more about our pioneering science and our
vital medicines, visit www.amgen.com.
CONTACT: Amgen, Thousand Oaks
David Polk, 805-447-4613 (media)
John Shutter, 805-447-1060 (investors)